Literature DB >> 11882583

Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells.

Raghvendra K Dubey1, Delbert G Gillespie, Paul J Keller, Bruno Imthurn, Lefteris C Zacharia, Edwin K Jackson.   

Abstract

Metabolism of locally applied 17beta-estradiol (estradiol) to methoxyestradiols contributes to the growth inhibiting effects of estradiol on vascular smooth muscle cells via an estrogen receptor (ER)-independent mechanism. Because vascular smooth muscle cells are phenotypically similar to glomerular mesangial cells, it is feasible that estradiol inhibits glomerular mesangial cell growth via a similar mechanism, and this possibility was investigated. In human glomerular mesangail cells, estradiol concentration dependently (1 to 100 nmol/L) inhibited serum-induced proliferation (cell number) and DNA ((3)[H]-thymidine incorporation) and collagen ((3)[H]-proline incorporation) synthesis. The inhibitory effects of estradiol were mimicked by 2-hydroxyestradiol and 2-methoxyestradiol, metabolites of estradiol with little affinity for ERs. 2-Hydroxyestradiol and 2-methoxyestradiol were more potent growth inhibitors than estradiol. The inhibitory effects of estradiol were enhanced by CYP450 inducers 3-methylcholanthrene (10 micromol/L) and phenobarbital (10 micromol/L) and blocked by the CYP450 inhibitor 1-aminobenzotriazole (10 micromol/L). The growth inhibitory effects of estradiol were also blocked by quercetin (10 micromol/L) and OR 486 (10 micromol/L) inhibitors of catechol-O-methyltransferase (converts catecholestradiols to methoxyestradiols). ICI182780 (ER antagonist with ER binding affinity similar to estradiol) blocked the growth inhibitory effects of estradiol (1 to 100 nmol/L) only at concentrations (>50 micromol/L) that inhibited estradiol metabolism to catecholestradiols. The growth inhibitory effects of 2-hydroxyestradiol were abrogated by quercetin and OR486 (two structurally dissimilar catechol-O-methyltransferase inhibitors), but not by ICI182780. However, the growth inhibitory effects of 2-methoxyestradiol were unaltered by catechol-O-methyltransferase inhibitors and ICI182780. In conclusion, our findings provide the first evidence that methoxyestradiols mediate the growth inhibitory effects of locally applied estradiol on glomerular mesangial cell growth via an ER-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882583     DOI: 10.1161/hy0202.103297

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  13 in total

1.  Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection.

Authors:  Federica Barchiesi; Eliana Lucchinetti; Michael Zaugg; Omolara O Ogunshola; Matthew Wright; Markus Meyer; Marinella Rosselli; Sara Schaufelberger; Delbert G Gillespie; Edwin K Jackson; Raghvendra K Dubey
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Differential effects of continuous and intermittent 17beta-estradiol replacement and tamoxifen therapy on the prevention of glomerulosclerosis: modulation of the mesangial cell phenotype in vivo.

Authors:  Michael Karl; Mariana Berho; Judith Pignac-Kobinger; Gary E Striker; Sharon J Elliot
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Sexual dimorphism: the aging kidney, involvement of nitric oxide deficiency, and angiotensin II overactivity.

Authors:  Chris Baylis
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-09-07       Impact factor: 6.053

Review 4.  Changes in renal hemodynamics and structure in the aging kidney; sexual dimorphism and the nitric oxide system.

Authors:  Chris Baylis
Journal:  Exp Gerontol       Date:  2005-04       Impact factor: 4.032

5.  Disruption of the cytochrome P-450 1B1 gene exacerbates renal dysfunction and damage associated with angiotensin II-induced hypertension in female mice.

Authors:  Brett L Jennings; Joseph A Moore; Ajeeth K Pingili; Anne M Estes; Xiao R Fang; Alie Kanu; Frank J Gonzalez; Kafait U Malik
Journal:  Am J Physiol Renal Physiol       Date:  2015-02-18

6.  Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy.

Authors:  Alexis Dixon; Corinne C Wells; Sandhya Singh; Regina Babayan; Christine Maric
Journal:  Am J Nephrol       Date:  2007-02-15       Impact factor: 3.754

7.  Sexual dimorphism, the aging kidney, and involvement of nitric oxide deficiency.

Authors:  Chris Baylis
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

8.  Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model.

Authors:  Qing-Hua Liu; Ding-Guo Li; Xin Huang; Chun-Hua Zong; Qin-Fang Xu; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

9.  2-methoxyestradiol plasma levels are associated with clinical severity indices and biomarkers of preeclampsia.

Authors:  Miriam Pertegal; Francisco J Fenoy; Barbara Bonacasa; Jaime Mendiola; Juan L Delgado; Moises Hernández; Miguel G Salom; Vicente Bosch; Isabel Hernández
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

10.  Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.

Authors:  Nilaksh Gupta; Jennifer A Buffa; Adam B Roberts; Naseer Sangwan; Sarah M Skye; Lin Li; Karen J Ho; John Varga; Joseph A DiDonato; W H Wilson Tang; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-26       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.